FAKTOR OPTIONSSCHEIN - ELI LILLY & CO | Delayed Deutsche Boerse AG 06:50:36 2024-07-17 am EDT | ||
| 52.24 EUR | -9.62% |
|
| Current month | +9.18% | ||
| 1 month | +19.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 52.24 | -9.62% |
| 24-07-16 | 57.8 | -2.63% |
| 24-07-15 | 59.36 | +1.30% |
| 24-07-12 | 58.6 | +3.72% |
| 24-07-11 | 56.5 | -2.18% |
Delayed Quote Deutsche Boerse AG
Last update July 17, 2024 at 06:50 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PD3LLY |
| ISIN | DE000PD3LLY5 |
| Date issued | 2021-09-15 |
| Strike | 941.6 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 61.79 € |
|---|---|
| Lowest since issue | 1.69 € |
| Spread | 0.97 € |
| Spread % | 1.83% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
901.5
USD
Spread / Average Target
-4.26%
- Stock Market
- Certificates
- Certificat
